Swiss Bank UBS Pays Fine Related To U.S. Tax Avoidance Scheme
Swiss bank UBS (UBS) has agreed to pay a fine of $511 million U.S. to settle a criminal case brought against former rival Credit Suisse for its role in helping American taxpayers hide more than $4 billion U.S. in offshore accounts.According to the U.S. Department of Justice, Credit Suisse helped Americans hide billions of dollars in at least 475 numbered bank accounts over the years. UBS acquired Credit Suisse in 2023 for $3.2 billion U.S. and has since absorbed the failed lender.The U.S. Justice Department says Credit Suisse conspired with “ultra-high-net-worth and high-net-worth individual clients” to help them hide money from the American government. Specifically, Credit Suisse helped wealthy Americans evade their U.S. tax obligations between the years 2010 and 2021.In a statement, UBS said that it was “not involved in the underlying conduct and has zero tolerance for tax evasion… With this resolution, UBS is pleased to have resolved another of Credit Suisse’s legacy issues.”Credit Suisse was taken over by UBS following years of financial losses and trading scandals. Credit Suisse had lost nearly 40% of its deposits in late 2022 as clients pulled money from the troubled lender.In 2022, Credit Suisse reported a full-year net loss of $7.86 billion U.S. before the Swiss government intervened and brokered a takeover by UBS.The stock of UBS has risen 2% this year and is currently trading at $30.77 U.S. per share on the New York Stock Exchange (NYSE).
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


